Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Bristol Myers announces EC approval of Breyanzi
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Medical Dialogues19h
Bristol Myers Squibb gets European Commission nod for Breyanzi for follicular lymphoma
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...
Bristol Myers Gets Expanded European Approval for Breyanzi
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
Investing2d
Bristol Myers Squibb’s Breyanzi gets EU nod for lymphoma treatment
PRINCETON, N.J. - The European Commission has approved Breyanzi, a treatment developed by Bristol Myers Squibb (NYSE:BMY), a pharmaceutical giant with $48.3 billion in revenue and an impressive 75 ...
Investing.com Australia2d
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy
Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...
Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Dividend On Common Stock And US$0.50 On Preferred Stock
Bristol-Myers Squibb (NYSE:BMY) recently declared a quarterly dividend of $0.62 per share on its common stock, reinforcing ...